Ascendis Pharma: Yuviwel Approved Despite Legal Challenges
Source: SeekingAlpha
2026-03-03 12:05:28 ET
Ascendis Pharma ( ASND ) announced the FDA approval of Yuviwel (navepegritide/TransCon CNP) for the treatment of children with achondroplasia. The regulatory decision comes despite the legal challenges by competitor BioMarin ( BMRN )....
Read the full article on Seeking Alpha
For further details see:
Ascendis Pharma: Yuviwel Approved Despite Legal Challenges
Ascendis Pharma A/S
NASDAQ: ASND
ASND Trading
0.99% G/L:
$238.53 Last:
326,818 Volume:
$236.64 Open:
ASND Latest News
March 02, 2026 08:43:00 am
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
February 27, 2026 05:57:16 pm
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
ASND Stock Data
$13,394,473,228
60,082,592
N/A
105
N/A
Biotechnology & Life Sciences
Healthcare
DK
Hellerup
